Trial · NCT03635567
Adverse events969
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 969
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Pembrolizumab+Chemotherapy | 182 | 307 | 264 |
| other | Anaemia | Blood and lymphatic system disorders | Placebo+Chemotherapy | 159 | 309 | 247 |
| other | Anaemia | Blood and lymphatic system disorders | Pembrolizumab (Second Course) | 2 | 12 | 2 |
| other | Leukopenia | Blood and lymphatic system disorders | Pembrolizumab+Chemotherapy | 40 | 307 | 71 |
| other | Leukopenia | Blood and lymphatic system disorders | Placebo+Chemotherapy | 33 | 309 | 55 |
| other | Leukopenia | Blood and lymphatic system disorders | Pembrolizumab (Second Course) | 2 | 12 | 2 |
| other | Lymphopenia | Blood and lymphatic system disorders | Pembrolizumab+Chemotherapy | 15 | 307 | 29 |
| other | Lymphopenia | Blood and lymphatic system disorders | Placebo+Chemotherapy | 7 | 309 | 7 |
| other | Lymphopenia | Blood and lymphatic system disorders | Pembrolizumab (Second Course) | 1 | 12 | 1 |
| other | Neutropenia | Blood and lymphatic system disorders | Pembrolizumab+Chemotherapy | 71 | 307 | 142 |
| other | Neutropenia | Blood and lymphatic system disorders | Placebo+Chemotherapy | 58 | 309 | 115 |
| other | Neutropenia | Blood and lymphatic system disorders | Pembrolizumab (Second Course) | 0 | 12 | 0 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Pembrolizumab+Chemotherapy | 60 | 307 | 90 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Placebo+Chemotherapy | 60 | 309 | 101 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Pembrolizumab (Second Course) | 0 | 12 | 0 |
| other | Ear discomfort | Ear and labyrinth disorders | Pembrolizumab+Chemotherapy | 0 | 307 | 0 |
| other | Ear discomfort | Ear and labyrinth disorders | Placebo+Chemotherapy | 2 | 309 | 2 |
| other | Ear discomfort | Ear and labyrinth disorders | Pembrolizumab (Second Course) | 1 | 12 | 1 |
| other | Hyperthyroidism | Endocrine disorders | Pembrolizumab+Chemotherapy | 24 | 307 | 26 |
| other | Hyperthyroidism | Endocrine disorders | Placebo+Chemotherapy | 9 | 309 | 10 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03635567/events